Kymera in the News
Read about breakthroughs, clinical advancements, and ongoing work to develop new medicines at Kymera.
Featured Perspectives
Fierce Biotech: Sanofi takes inflammatory disease protein degrader forward as Kymera shares glimpse of efficacy
Kymera Therapeutics has generated the first early clinical evidence that its targeted protein degradation technology works in immune-inflammatory diseases.
Nasdaq: Kymera (KYMR) Up on Positive Data From Phase I Study on KT-474
KYMR announced positive clinical data from a phase I study evaluating its highly selective, orally bioavailable IRAK4 degrader, KT-474, for the treatment of patients with hidradenitis suppurativa (“HS”) and atopic dermatitis (“AD”).
Boston Globe: Top Places to Work in Massachusetts 2022
Kymera’s wellness stipend, instituted at the beginning of the year, is designed to let workers know “we care about them, and want to give them a way to care for themselves,” says Karen Weisbach, vice president of people and culture.
PharmaVoice: The 2022 PharmaVoice 100 – Nello Mainolfi
Nello Mainolfi, co-founder, president and CEO of Kymera Therapeutics, has an empty prescription bottle on his desk — a bottle that he hopes to soon fill with with one of the biotech company’s drugs.
FastCompany: These innovative projects are changing the health industry
The health category of Fast Company’s World Changing Ideas Awards honors medical innovations that save lives, extend longevity, or increase access to care.
Timmerman Report: Targeted Small Molecule Protein Degraders, Nello Mainolfi on the Long Run
Kymera is working on targeted protein degraders. These are orally available small molecule compounds. Many in biopharma are excited about them because they have a clever design that allows them to go after targets that have previously been out of reach for small molecules. Nello Mainolfi, PhD, Founder, President & CEO shares more about Kymera’s work and mission.